Quillivant XR

Tris Pharma's once-daily 12-hour extended-release liquid methylphenidate, FDA-approved 2012 for pediatric ADHD ages 6-17. Same drug as Ritalin/Concerta with similar PK profile (12-hour duration, ascending curve via LiquiXR ion-exchange resin) but brand-only at ~$300-450/month with no AB-rated generic. Niche use case: pediatric patients who cannot swallow pills (dysphagia, autism, very young, feeding tubes). For Dylan: NOT-RELEVANT HIGH — no clinical scenario where Quillivant beats Concerta generic at 1/10th the cost. Methylphenidate-class is already SKIP-FOR-NOW; Quillivant adds nothing on top of that decision.

Drug: Quillivant XR contains the same racemic methylphenidate hydrochloride as Ritalin and Concerta. The d-threo enantiomer (sold isolated as Focalin) does ~90% of the active work. Mechanism is identical to Ritalin: blocks the dopamine transporter (DAT) and norepinephrine transporter (NET), raising synaptic dopamine and norepinephrine in prefrontal cortex (focus, executive function) and dorsal striatum (motor/attention gating). It does NOT cause vesicular release like amphetamines — just blocks reuptake of what's already being released.

Delivery — LiquiXR ion-exchange technology:

Quillivant XR is an oral suspension (25 mg/5 mL after reconstitution with water by the dispensing pharmacist) using Tris Pharma's proprietary LiquiXR (formerly OralXR+) platform. The science:

1. Methylphenidate is bound to a sulfonate ion-exchange resin (sulfonated polystyrene microparticles, similar in principle to cholestyramine but sized for sustained drug release).
2. Coated resin particles are suspended in a flavored aqueous vehicle.
3. In the GI tract, sodium and potassium cations from gastric fluids displace the drug from the resin's sulfonate sites, releasing it gradually over ~12 hours.
4. ~20% of the dose is unbound (immediate-release fraction, in solution form for fast onset).
5. ~80% of the dose is resin-bound (extended-release fraction, releasing as cation exchange progresses through the GI tract).

This produces a plasma profile similar to Concerta's OROS — initial loading from the unbound fraction, then a gradual rise as the resin releases drug over the day. Tris Pharma's bioequivalence studies (Wigal 2013) demonstrated comparable AUC and Cmax to multiple-dose IR methylphenidate dosed BID/TID.

Pharmacokinetics:

• Oral bioavailability ~22-30% (same as Ritalin/Concerta — first-pass metabolism dominates)
• Tmax ~5 hours (initial peak from immediate-release fraction may show earlier shoulder around 1-2 hr)
• Half-life ~5.6 hours (apparent, longer than IR's 3.5 hr due to extended-release flip-flop kinetics — absorption-limited rather than elimination-limited)
• Effective duration ~12 hours (label claim, supported by classroom analog studies showing efficacy at 12 hr post-dose)
• Metabolism: Primarily by carboxylesterase 1 (CES1) — NOT CYP-mediated. Same as all methylphenidate formulations. Major metabolite: ritalinic acid (inactive). CYP2D6 is NOT involved.
• Excretion: Renal, primarily as ritalinic acid. ~60-86% recovered in urine.

Why a liquid? (the actual question): Pill-swallowing difficulty is genuinely common in pediatrics. Children under 6 (off-label) have undeveloped swallowing reflex; children with autism spectrum disorder often have profound oral aversions; patients with developmental disabilities, severe GERD, dysphagia, or feeding tubes need liquid options. Before Quillivant (2012), the only liquid methylphenidate was Methylin Oral Solution — an immediate-release product requiring BID dosing, which is hard for school-age children. Quillivant's value proposition: liquid + once-daily + 12-hour coverage = practical for the pediatric dysphagia population.

For adults: this need is rare. Most adults can swallow tablets. Adult dysphagia (post-stroke, ALS, severe GERD, esophageal stricture) does exist but is uncommon, and even then crushed/chewable IR formulations or compounded suspensions can substitute at lower cost.